TaMoVac II

HIV vaccine trial capacity building in Tanzania and Mozambique by continued exploration of optimal DNA priming and MVA boosting strategies

Exploring new strategies for needle free vaccination

What is this study about?

It is estimated that over 33 million people are living with HIV around the world. There is currently no cure and although there are drugs available that can manage HIV, the majority of infected people are unable to access treatment. In 2009 it was estimated that 2.7 million people became newly-infected worldwide.

Therefore, developing a vaccine is a main priority in HIV research and although many options have been explored, an effective vaccine has yet to be developed.

Previous studies have shown that using an electric current instead of a needle to administer a vaccine can be more efficient.

This study will be using this method to administer a DNA plasmid vaccine which has already been tested using more conventional methods. It will assess whether the method is safe and also whether this route gives rise to a better immune response against HIV.

Type of study

Randomised trial

Contact details


Who is funding the study?


When is it taking place?

Follow-up due to be completed by June 2015.

Where is it taking place?

Tanzania (Mbeya, Dar es Salaam), and Mozambique (Maputo).

Who is included?

198 healthy, HIV uninfected adults, comprising 80 each from two sites in Tanzania (Mbeya and Dar es Salaam) and 38 from Mozambique (Maputo).